Alice Tsang Shaw
#123,382
Most Influential Person Now
Alice Tsang Shaw's AcademicInfluence.com Rankings
Alice Tsang Shawbiology Degrees
Biology
#7623
World Rank
#10573
Historical Rank
Molecular Biology
#894
World Rank
#917
Historical Rank
Neuroscience
#1006
World Rank
#1047
Historical Rank
Biochemistry
#1053
World Rank
#1168
Historical Rank
Download Badge
Biology
Alice Tsang Shaw's Degrees
- PhD Biomedical Sciences Stanford University
- Bachelors Biochemistry University of California, Berkeley
Why Is Alice Tsang Shaw Influential?
(Suggest an Edit or Addition)Alice Tsang Shaw's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (2010) (3445)
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2011) (3017)
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009) (1717)
- Tumour heterogeneity and resistance to cancer therapies (2018) (1686)
- Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017) (1553)
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012) (1212)
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. (2012) (1194)
- Crizotinib in ROS1-rearranged non-small-cell lung cancer. (2014) (1089)
- Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) (938)
- Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (875)
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011) (875)
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis (2016) (845)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (2018) (816)
- Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. (2004) (807)
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. (2019) (711)
- The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. (2014) (697)
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population (2009) (646)
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer (2014) (627)
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. (2013) (627)
- ROS1 rearrangements define a unique molecular class of lung cancers. (2012) (617)
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). (2017) (561)
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. (2015) (555)
- Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (543)
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK (2011) (540)
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. (2016) (491)
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013) (478)
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer (2016) (453)
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (2018) (451)
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. (2016) (421)
- Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer (2014) (421)
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. (2017) (411)
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. (2015) (403)
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. (2016) (401)
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. (2017) (400)
- ALK in lung cancer: past, present, and future. (2013) (385)
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. (2016) (373)
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. (2015) (373)
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. (2011) (353)
- Targeting ALK: Precision Medicine Takes on Drug Resistance. (2017) (333)
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. (2020) (327)
- Novel targets in non-small cell lung cancer: ROS1 and RET fusions. (2013) (298)
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. (2016) (293)
- Acquired resistance to crizotinib from a mutation in CD74-ROS1. (2013) (292)
- Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. (2013) (292)
- Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. (2018) (283)
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. (2019) (281)
- Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. (2016) (280)
- Targeting Anaplastic Lymphoma Kinase in Lung Cancer (2011) (276)
- Tyrosine kinase gene rearrangements in epithelial malignancies (2013) (273)
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib (2014) (259)
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. (2018) (248)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2019) (241)
- ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. (2014) (237)
- TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. (2020) (228)
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine (2015) (216)
- Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. (2011) (215)
- Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. (2013) (212)
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. (2019) (209)
- Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress (2011) (208)
- Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies (2014) (207)
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. (2018) (206)
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer (2015) (194)
- Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study (2018) (194)
- Recent Advances in Targeting ROS1 in Lung Cancer (2017) (186)
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. (2018) (184)
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 (2019) (184)
- Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. (2017) (182)
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. (2019) (170)
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer (2014) (170)
- Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). (2012) (168)
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib (2015) (168)
- Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). (2010) (157)
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (2016) (153)
- Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). (2011) (152)
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib (2015) (152)
- Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. (2012) (146)
- Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. (2017) (135)
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors (2018) (134)
- Resisting Resistance: Targeted Therapies in Lung Cancer. (2016) (133)
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer (2012) (131)
- Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. (2018) (130)
- Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. (2007) (129)
- Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping (2016) (127)
- Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. (2015) (123)
- Crizotinib and testing for ALK. (2011) (122)
- Crizotinib resistance: implications for therapeutic strategies. (2016) (121)
- Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care (2017) (119)
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer (2015) (118)
- Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer (2018) (115)
- Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (2012) (114)
- Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. (2019) (111)
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer (2015) (110)
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. (2019) (108)
- The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. (2013) (108)
- KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (106)
- Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. (2018) (102)
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013) (100)
- Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. (2018) (98)
- Clinical Activity of Alectinib in Advanced RET‐Rearranged Non–Small Cell Lung Cancer (2016) (89)
- Safety of Combined PD‐1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer (2018) (88)
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity (2019) (87)
- ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). (2015) (86)
- Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. (2018) (86)
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas (2015) (85)
- Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (2016) (85)
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer (2017) (83)
- ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). (2015) (82)
- MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer (2020) (82)
- First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. (2013) (80)
- Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. (2010) (79)
- Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer (2017) (78)
- SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. (2014) (75)
- Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. (2013) (75)
- ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC (2018) (74)
- Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (2014) (73)
- Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. (2016) (73)
- Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. (2015) (73)
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models (2019) (72)
- Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies (2016) (70)
- Clinical Management of Adverse Events Associated with Lorlatinib. (2019) (70)
- Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer (2019) (68)
- Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer (2014) (68)
- Molecular Analysis of Plasma From Patients With ROS1‐Positive NSCLC (2019) (67)
- Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). (2019) (67)
- Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). (2015) (66)
- Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer (2018) (66)
- Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer (2017) (65)
- Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). (2013) (64)
- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer (2020) (57)
- Mouse models of human non-small-cell lung cancer: raising the bar. (2005) (57)
- Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. (2018) (56)
- Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50% (2019) (54)
- Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. (2016) (53)
- Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. (2021) (53)
- Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. (2016) (53)
- Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. (2016) (52)
- MET amplification (amp) as a resistance mechanism to osimertinib. (2017) (52)
- Combined Pan‐HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study (2016) (51)
- Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial (2017) (51)
- Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor (2017) (49)
- Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions (2018) (48)
- Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. (2011) (48)
- Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. (2015) (47)
- Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. (2016) (46)
- Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (2014) (46)
- Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. (2019) (46)
- Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). (2012) (45)
- Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) (2012) (45)
- Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. (2021) (44)
- STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. (2015) (44)
- Complex renal cysts associated with crizotinib treatment (2015) (43)
- Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment (2018) (43)
- Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study (2019) (42)
- 1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. (2014) (41)
- Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer (2019) (40)
- Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study (2016) (40)
- First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. (2012) (39)
- Developing biomarker-specific end points in lung cancer clinical trials (2015) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer (2017) (39)
- Scientific Advances in Thoracic Oncology 2016. (2017) (39)
- Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. (2018) (37)
- Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. (2015) (37)
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors (2020) (37)
- New targets in advanced NSCLC: EML4-ALK. (2011) (37)
- The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (2012) (36)
- Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). (2015) (36)
- OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer (2017) (36)
- Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC. (2020) (36)
- Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (2017) (35)
- Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC). (2017) (35)
- 1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1. (2014) (34)
- Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer. (2020) (33)
- Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer (2015) (33)
- Resistance looms for KRASG12C inhibitors (2020) (33)
- Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
- ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials. (2019) (32)
- Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle (2016) (31)
- Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. (2018) (31)
- Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial (2016) (31)
- Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer (2021) (31)
- Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM) (2016) (31)
- Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. (2020) (30)
- Efficacy of Alectinib in Patients with ALK‐Positive NSCLC and Symptomatic or Large CNS Metastases (2019) (29)
- Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC (2018) (28)
- Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement (2012) (28)
- Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)‐positive (ALK+) non‐small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330 (2016) (28)
- Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. (2017) (27)
- Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. (2018) (27)
- Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? (2016) (26)
- Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer. (2020) (26)
- Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics? (2016) (25)
- ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC) (2019) (25)
- A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies (2012) (24)
- Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer. (2019) (23)
- Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2017) (23)
- BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL (2014) (23)
- Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results (2016) (23)
- Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors (2012) (23)
- Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (2017) (23)
- Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. (2014) (22)
- OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 (2018) (22)
- Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC (2017) (22)
- A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (2015) (21)
- Future of Early Detection of Lung Cancer: The Role of Mouse Models (2005) (21)
- Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer (2018) (20)
- Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC (2019) (20)
- Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations (2019) (20)
- Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. (2012) (20)
- Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study) (2019) (19)
- LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study (2020) (19)
- Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 (2014) (19)
- Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition (2020) (19)
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. (2019) (19)
- BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency (2020) (19)
- Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions. (2015) (19)
- Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001 (2016) (19)
- Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. (2016) (18)
- 1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. (2014) (18)
- Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer? (2012) (18)
- A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. (2021) (18)
- A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). (2018) (18)
- Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib. (2016) (17)
- First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. (2018) (17)
- Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies (2020) (17)
- Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. (2019) (17)
- Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations (2018) (17)
- Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. (2020) (17)
- Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. (2019) (17)
- Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. (2016) (17)
- Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. (2020) (17)
- Ef fi cacy of Platinum/Pemetrexed Combination Chemotherapy in ALK -Positive NSCLC Refractory to Second-Generation ALK Inhibitors (2020) (17)
- Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. (2018) (17)
- Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping (2016) (17)
- 1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study (2017) (17)
- Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy (2014) (17)
- The new kid on the block: RET in lung cancer. (2013) (17)
- MA07.11 Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (16)
- Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 (2019) (16)
- Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007. (2016) (16)
- Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (16)
- Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (2019) (16)
- Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. (2019) (15)
- Non-small cell lung cancer, locally advanced (2012) (15)
- Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2015) (15)
- Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer (2018) (14)
- Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC). (2017) (14)
- Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. (2018) (14)
- Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK‐rearranged (ALK+) non‐small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND‐1 and ASCEND‐2 trials: 141PD (2016) (14)
- Expanding the Roster of ROS1 Inhibitors. (2017) (13)
- Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. (2011) (13)
- Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib (2012) (13)
- MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer (2017) (13)
- Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements (2020) (12)
- Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update (2015) (12)
- Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC). (2016) (12)
- Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer. (2020) (12)
- Lung Cancer: A Wily Genetic Opponent (2017) (12)
- Crizotinib in ROS1-rearranged non-small-cell lung cancer. (2015) (11)
- A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. (2015) (11)
- A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis (2017) (11)
- Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. (2015) (11)
- Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer. (2010) (11)
- Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. (2014) (11)
- LBA4EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON–SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (2015) (10)
- Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). (2019) (10)
- A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. (2010) (10)
- Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (2020) (10)
- Phase I Trial of Irreversible Pan-Erbb Inhibitor Dacomitinib (DAC) in Combination with ALK/MET Inhibitor Crizotinib (CRIZ) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (10)
- OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials (2017) (10)
- 1344PBrigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial (2017) (10)
- Hypogonadism related to crizotinib therapy (2012) (9)
- Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status. (2017) (9)
- Association between circulating tumor DNA burden and disease burden in patients with ALK‐positive lung cancer (2020) (9)
- Abstract 5593: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers (2012) (9)
- Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort (2019) (9)
- Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. (2019) (9)
- ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. (2012) (9)
- A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC (2020) (9)
- Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy. (2014) (9)
- Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. (2020) (8)
- Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial (2022) (8)
- APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer (2021) (8)
- Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2016) (8)
- 9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC) (2011) (8)
- Clinicopathologic features of EML4-ALK mutant lung cancer. (2009) (8)
- Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial (2022) (8)
- OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC (2018) (7)
- J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer (2017) (7)
- Crizotinib Resensitization by Compound Mutation. (2016) (7)
- Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. (2017) (7)
- Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. (2020) (7)
- Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History (2019) (7)
- SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. (2011) (7)
- JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial (2017) (7)
- Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
- Genotyping lung cancer is an investment in the future. (2014) (7)
- Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC). (2018) (7)
- A phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). (2013) (7)
- MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK‐inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology (2016) (6)
- Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study (2021) (6)
- Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). (2014) (6)
- Acquired resistance to crizotinib from a mutation in CD74-ROS1. (2013) (6)
- Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy (2017) (6)
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). (2018) (6)
- Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC. (2018) (6)
- 369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) (2010) (6)
- MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study (2018) (6)
- P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer (2018) (6)
- Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease. (2022) (6)
- Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. (2018) (5)
- Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer (2014) (5)
- Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. (2017) (5)
- Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both? (2012) (5)
- Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies (2019) (5)
- Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results. (2016) (5)
- Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer (2018) (5)
- A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). (2012) (5)
- Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer. (2015) (5)
- Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. (2020) (5)
- Clinician Perspectives on Current Issues in Lung Cancer Drug Development (2016) (5)
- Lipodermatosclerosis secondary to pemetrexed use. (2015) (5)
- Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study. (2018) (5)
- Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC) (2013) (4)
- Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. (2017) (4)
- Abstract 919: AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib. (2013) (4)
- OA 12.02 Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions (2017) (4)
- Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer (2017) (4)
- 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results (2016) (4)
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. (2022) (4)
- Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001. (2019) (4)
- 1332TiPTWO PHASE III STUDIES EVALUATING CERITINIB IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): ASCEND-4 AND ASCEND-5. (2014) (4)
- Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial (2016) (4)
- Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC (2012) (4)
- MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases (2019) (3)
- SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). (2010) (3)
- A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression. (2020) (3)
- 150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2016) (3)
- Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial. (2017) (3)
- Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (2018) (3)
- BMET-18ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA (2015) (3)
- Raising the bar on first-line immunotherapy in lung cancer. (2017) (3)
- MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC (2019) (3)
- MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC (2021) (3)
- Preliminary Clinical Activity of Repotrectinib (TPX‐0005) in Advanced ROS1 Fusion‐Positive Non‐Small Cell Lung Cancer: OA09 (2018) (3)
- MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC (2017) (3)
- Fast, Food and Ceritinib in ALK-Positive NSCLC. (2017) (3)
- Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC). (2013) (3)
- Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting (2019) (3)
- Targeted inhibition in tumors with ALK dependency. (2013) (3)
- Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). (2016) (3)
- Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse (2022) (3)
- Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies. (2019) (2)
- Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an NTRK gene fusion. (2017) (2)
- 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ) (2016) (2)
- Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM). (2016) (2)
- Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer (2014) (2)
- Abstract CT129: Phase 2 study of cabozantinib in patients with non-breast, non-prostate cancer with bone metastasis (2017) (2)
- Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population. (2018) (2)
- 111PCERITINIB TREATMENT OF PATIENTS (PTS) WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES: ASCEND-1 TRIAL EXPERIENCE (2015) (2)
- Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI). (2019) (2)
- BRAF Mutation Class and Clinical Outcomes—Response (2019) (2)
- Continuation of ceritinib beyond disease progression is associated with prolonged post‐progression survival (PPS) in ALK+ NSCLC: 178P (2016) (2)
- The challenges of repeat biopsies at acquired resistance to EGFR TKIs. (2016) (2)
- Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study. (2021) (2)
- Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC) (2020) (2)
- ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced? (2017) (2)
- Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC. (2018) (2)
- OA 07.05 Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms (2017) (2)
- P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer (2019) (2)
- Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). (2017) (2)
- Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial. (2019) (2)
- Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma. (2015) (2)
- Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). (2018) (2)
- MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC (2017) (2)
- BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation. (2018) (2)
- Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC) (2012) (2)
- 1299PCLINICAL ACTIVITY OF CRIZOTINIB IN ROS1-REARRANGED NON-SMALL CELL LUNG CANCER. (2014) (2)
- Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies. (2016) (2)
- MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant (2017) (1)
- Lorlatinib in ALK-or ROS 1-rearranged non-small cell lung cancer : an international , multicenter , open-label phase 1 trial (2018) (1)
- A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC). (2013) (1)
- Refining precision cancer therapy in ALK-positive NSCLC (2019) (1)
- One Allele's Loss Is Another's Gain: Alterations of NKX2–8 in Non–Small Cell Lung Cancer (2010) (1)
- Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation (2018) (1)
- Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer) (2010) (1)
- 99OPHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)–POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES (2015) (1)
- Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3. (2016) (1)
- Early versus On-Demand Tube Feeding in Pancreatitis (2015) (1)
- Targeting ALK Rearrangements (2014) (1)
- Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib (2017) (1)
- P3.02b-103 Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing: Topic: EGFR RES (2017) (1)
- Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations (2021) (1)
- Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs. (2019) (1)
- ALK-positive lung cancer: a moving target (2023) (1)
- Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) (2015) (1)
- Efficacy and Patient (PT)-Reported Outcomes (PROS) aith Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Phase II Trial (2012) (1)
- 1308PDPreliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC) (2017) (1)
- A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment (2012) (1)
- Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data (2018) (1)
- Safety of lorlatinib in subgroups of patients from a phase I/II trial (2019) (1)
- Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials (2017) (1)
- Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases (2020) (1)
- 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression (2020) (1)
- Multiplex Genetic Analysis In Lung Cancer Using Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (2012) (1)
- 1380TiPA randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (2017) (1)
- Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models (2015) (1)
- Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer (2013) (1)
- O1–131PHASE III STUDY OF CRIZOTINIB VS. CHEMOTHERAPY IN ADVANCED ALK+ NSCLC: PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (2013) (1)
- ePoster SessionsLocal Control and Distant Brain Failure in Patients Treated With Concurrent Radiation and PD-1/PDL-1 Inhibitors (2017) (1)
- Abstract 3590: Resistance mechanisms to ALK inhibitors (2015) (1)
- Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer (2022) (1)
- Emre Ozkumur Sorting of Rare Circulating Tumor Cells Independent − Dependent and − Inertial Focusing for Tumor Antigen (2013) (1)
- Abstract PL01-04: Mechanisms of acquired resistance to ALK/ROS1 inhibitors. (2013) (1)
- Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (2018) (1)
- Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses. (2022) (1)
- OA15.01 Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial (2019) (1)
- Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies (2016) (1)
- Newer Targeted Agents in NSCLC: ALK Inhibitors (2018) (0)
- Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. (2021) (0)
- Abstract 657: Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer (2022) (0)
- Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (0)
- Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance (2021) (0)
- 1311PLKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma (2017) (0)
- P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
- Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer (2022) (0)
- Future of EarlyDetectionof LungCancer : TheRole ofMouseModels (2005) (0)
- Rociletinib-associated cataracts in EGFR-mutant NSCLC. (2016) (0)
- P3.02a-015 Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis: Topic: ALK Clinical (2017) (0)
- Experts Discuss the Promises and Challenges with Targeted Therapies (2014) (0)
- P1.01-016 Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib (2017) (0)
- Abstracts (2009) (0)
- A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib (2022) (0)
- Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC) (2017) (0)
- 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study (2015) (0)
- Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. (2022) (0)
- Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC). (2018) (0)
- Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative (2020) (0)
- 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases (2015) (0)
- Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer: Significance of Mutations in EGFR, ALK, or KRAS on Radiation Therapy Response and Survival (2013) (0)
- CNS Radiation-Related Adverse Events in Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors (2017) (0)
- Abstract 3715: Discovery of novel targets for effective combination drug therapy in ALK+ NSCLC patient derived models of acquired resistance (2014) (0)
- Abstract 2461: Design and synthesis of AZD3463, a novel orally bioavailable dual ALK and IGF1R inhibitor, inhibits growth of crizotinib resistance cell lines with multiple mechanisms of acquired resistance. (2013) (0)
- Alectinib and ALK-Positive Non-Small Cell Lung Cancer Q & A with (0)
- Abstract 4465: Concurrent roles for IGF1R and EGFR in driving acquired resistance to crizotinib and ability to overcome with a combination of the ALK/IGF1R inhibitor AZD3463 and Iressa. (2013) (0)
- P2.01-04 NCI-NRG Oncology ALK PROTOCOL (NRG-LU003): A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients (2019) (0)
- Abstract 2972: Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity (2018) (0)
- Phase II Study of Cabozantinib in Patients With Bone Metastasis (2022) (0)
- P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis (2017) (0)
- A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) (2012) (0)
- 1343PEfficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs (2017) (0)
- IS7. lung cancer (2012) (0)
- Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. (2017) (0)
- Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
- Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors. (2019) (0)
- Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients with Advanced NSCLC (2008) (0)
- An artificial intelligence approach to variant calling of ALK resistance mutations. (2019) (0)
- 1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (2021) (0)
- O-028: CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT (2012) (0)
- Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC (2018) (0)
- BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3 (2016) (0)
- PS02.22 Alectinib Following Prior ALK Tyrosine Kinase Inhibitor (TKI) Therapy: Results from the US Expanded Access Program (EAP): Topic: Medical Oncology (2017) (0)
- ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC). (2016) (0)
- Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms (2013) (0)
- Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. (2011) (0)
- Abstract #2344: Selective killing of K-ras mutant cancer cells by novel, small molecule inducers of oxidative stress (2009) (0)
- Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC). (2018) (0)
- Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. (2023) (0)
- MIS2. lung cancer clinical (2012) (0)
- Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib (2012) (0)
- Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (2017) (0)
- Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer (2023) (0)
- Abstract CT198: Expansion of Phase I/II study of olaparib and temozolomide in patients with relapsed small cell lung cancer (SCLC) and co-clinical trial in patient-derived xenografts (PDXs) for biomarker discovery (2019) (0)
- MA16.08 Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma (2018) (0)
- Biomarker discovery and preclinical validation using mouse models of lung cancer. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alice Tsang Shaw?
Alice Tsang Shaw is affiliated with the following schools:
